prikaz prve stranice dokumenta Pleiotropni učinci GLP-1 agonista
  Download
PDF 1.04 MB
master's thesis
Pleiotropni učinci GLP-1 agonista
Zagreb: University of Zagreb, Faculty of Pharmacy and Biochemistry, 2023. urn:nbn:hr:163:045935
Rotim, Tea
University of Zagreb
Faculty of Pharmacy and Biochemistry
Department of pharmacology

Institutional repository: Repository of Faculty of Pharmacy and Biochemistry University of Zagreb

Cite this document

Rotim, T. (2023). Pleiotropni učinci GLP-1 agonista (Master's thesis). Zagreb: University of Zagreb, Faculty of Pharmacy and Biochemistry. Retrieved from https://urn.nsk.hr/urn:nbn:hr:163:045935

Rotim, Tea. "Pleiotropni učinci GLP-1 agonista." Master's thesis, University of Zagreb, Faculty of Pharmacy and Biochemistry, 2023. https://urn.nsk.hr/urn:nbn:hr:163:045935

Rotim, Tea. "Pleiotropni učinci GLP-1 agonista." Master's thesis, University of Zagreb, Faculty of Pharmacy and Biochemistry, 2023. https://urn.nsk.hr/urn:nbn:hr:163:045935

Rotim, T. (2023). 'Pleiotropni učinci GLP-1 agonista', Master's thesis, University of Zagreb, Faculty of Pharmacy and Biochemistry, accessed 06 May 2024, https://urn.nsk.hr/urn:nbn:hr:163:045935

Rotim T. Pleiotropni učinci GLP-1 agonista [Master's thesis]. Zagreb: University of Zagreb, Faculty of Pharmacy and Biochemistry; 2023 [cited 2024 May 06] Available at: https://urn.nsk.hr/urn:nbn:hr:163:045935

T. Rotim, "Pleiotropni učinci GLP-1 agonista", Master's thesis, University of Zagreb, Faculty of Pharmacy and Biochemistry, Zagreb, 2023. Available at: https://urn.nsk.hr/urn:nbn:hr:163:045935

Metadata
TitlePleiotropni učinci GLP-1 agonista
Title (english)Pleiotropic effects of GLP1-agonists
AuthorTea Rotim
MentorPetra Turčić (mentor)
Committee memberPetra Turčić (predsjednik povjerenstva)
Committee memberLidija Bach-Rojecky (član povjerenstva)
Committee memberMarija Grdić Rajković (član povjerenstva)
GranterUniversity of Zagreb
Faculty of Pharmacy and Biochemistry
(Department of pharmacology)
Zagreb
Defense date and country2023-03-30, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Pharmacy
Pharmacy
Abstract
GLP-1 agonisti su lijekovi koji pripadaju skupini inkretinomimetika što znači da svoj osnovni hipoglikemijski mehanizam ostvaruju aktivacijom inkretinskog sustava koji omogućuje sekreciju inzulina ovisno o glukozi. Dijele se na kratkodjelujuće i dugodjelujuće te ovisno o aktivnosti i strukturi pokazuju različite farmakokinetske i farmakodinamske karakteristike. Veoma su dobro prihvaćeni kao terapija ŠBT2, no zahvaljujući sposobnosti smanjenja tjelesne mase neki se od njih registriraju i za liječenje pretilosti. Njihovi dodatni potencijali se godinama neiscrpno istražuju te pokazuju brojne pleiotropne učinke. Djelomično zahvaljujući činjenici da su GLP-1 receptori prisutni u brojnim tkivima jer putem njih ostvaruju svoje učinke, GLP-1 agonisti pokazali su kardioprotektivne, renoprotektivne, hepatoprotektivne i neuroprotektivne učinke, a brojne studije i dalje pokušavaju razlučiti njihove mehanizme kako bi se ovi lijekovi istaknuli kao nove moguće opcije u liječenju ne samo ŠBT2 i pretilosti, već i brojnih komorbiditeta koji prate ova stanja, a uključuju poremećaje vezane uz srce, bubrege, jetru i živčani sustav.
Abstract (english)
GLP-1 agonists are a group of incretin mimetic drugs, therefore they activate the incretin system as their primary goal which allows glucose-dependent insulin secretion. They can be divided into short-acting or long-acting agents depending on their activity and structure by which they differ in pharmacokinetic and pharmacodynamic profiles. They are widely accepted as T2DM therapy, yet some of them are used for managing obesity due to their ability to promote weight loss. Their additional potentials are being investigated with continuing efforts and have revealed multiple pleiotropic effects. Owing to the fact that GLP-1 receptors are present in multiple organ tissues, GLP-1 agonists have shown cardioprotective, renoprotective, hepatoprotective, and neuroprotective effects, while numerous studies are trying to elucidate their specific mechanisms for them to become potential novel therapy, not only for T2DM and obesity but also for numerous comorbidities that accompany these conditions and include heart, kidney, liver, and nervous system disorders.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:163:045935
Study programmeTitle: Pharmacy
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: magistar/magistra farmacije (magistar/magistra farmacije)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2023-04-14 09:46:56